Four cases of recurrent breast cancer effectively treated by the new ntitumor agent, CPT-11 (irinotecan)

Hiroyoshi Doihara, S. Takashima, N. Yokoyama

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Four cases of recurrent breast cancer effectively treated by CPT-11 were reported. These cases had undergone previous chemotherapy including adriamycin. Nevertheless, they developed no tolerance to such therapies and displayed good responsitivity to CPT-11. Effects on metastatic lesions: One was bone and three were soft tissues was observed after the end of one course therapy. The response periods were over 210 days, 431 days, 175 days and 73 days. Thus, it was suggested that early response to drug was important clinically and was significant for enhancing the quality of life of patients. Major adverse reactions were leukopenia and gastrointestinal symptoms such as nausea, vomiting and diarrhea (Grade 2-3). However, these could be well managed by symptomatic treatment and dose modification. The results suggested that CPT-11 was an effective agent against advanced or recurrent breast cancer, and especially useful for patients who had developed a tolerance to previous therapies.

Original languageEnglish
Pages (from-to)1263-1266
Number of pages4
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume21
Issue number8
Publication statusPublished - 1994
Externally publishedYes

Fingerprint

irinotecan
Breast Neoplasms
Leukopenia
Therapeutics
Doxorubicin
Nausea
Vomiting
Diarrhea
Quality of Life
Bone and Bones
Drug Therapy

Keywords

  • breast cancer
  • CPT-11
  • irinotecan

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Four cases of recurrent breast cancer effectively treated by the new ntitumor agent, CPT-11 (irinotecan). / Doihara, Hiroyoshi; Takashima, S.; Yokoyama, N.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 21, No. 8, 1994, p. 1263-1266.

Research output: Contribution to journalArticle

@article{c28297990dc04ba99aa0108ad9ca80b4,
title = "Four cases of recurrent breast cancer effectively treated by the new ntitumor agent, CPT-11 (irinotecan)",
abstract = "Four cases of recurrent breast cancer effectively treated by CPT-11 were reported. These cases had undergone previous chemotherapy including adriamycin. Nevertheless, they developed no tolerance to such therapies and displayed good responsitivity to CPT-11. Effects on metastatic lesions: One was bone and three were soft tissues was observed after the end of one course therapy. The response periods were over 210 days, 431 days, 175 days and 73 days. Thus, it was suggested that early response to drug was important clinically and was significant for enhancing the quality of life of patients. Major adverse reactions were leukopenia and gastrointestinal symptoms such as nausea, vomiting and diarrhea (Grade 2-3). However, these could be well managed by symptomatic treatment and dose modification. The results suggested that CPT-11 was an effective agent against advanced or recurrent breast cancer, and especially useful for patients who had developed a tolerance to previous therapies.",
keywords = "breast cancer, CPT-11, irinotecan",
author = "Hiroyoshi Doihara and S. Takashima and N. Yokoyama",
year = "1994",
language = "English",
volume = "21",
pages = "1263--1266",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "8",

}

TY - JOUR

T1 - Four cases of recurrent breast cancer effectively treated by the new ntitumor agent, CPT-11 (irinotecan)

AU - Doihara, Hiroyoshi

AU - Takashima, S.

AU - Yokoyama, N.

PY - 1994

Y1 - 1994

N2 - Four cases of recurrent breast cancer effectively treated by CPT-11 were reported. These cases had undergone previous chemotherapy including adriamycin. Nevertheless, they developed no tolerance to such therapies and displayed good responsitivity to CPT-11. Effects on metastatic lesions: One was bone and three were soft tissues was observed after the end of one course therapy. The response periods were over 210 days, 431 days, 175 days and 73 days. Thus, it was suggested that early response to drug was important clinically and was significant for enhancing the quality of life of patients. Major adverse reactions were leukopenia and gastrointestinal symptoms such as nausea, vomiting and diarrhea (Grade 2-3). However, these could be well managed by symptomatic treatment and dose modification. The results suggested that CPT-11 was an effective agent against advanced or recurrent breast cancer, and especially useful for patients who had developed a tolerance to previous therapies.

AB - Four cases of recurrent breast cancer effectively treated by CPT-11 were reported. These cases had undergone previous chemotherapy including adriamycin. Nevertheless, they developed no tolerance to such therapies and displayed good responsitivity to CPT-11. Effects on metastatic lesions: One was bone and three were soft tissues was observed after the end of one course therapy. The response periods were over 210 days, 431 days, 175 days and 73 days. Thus, it was suggested that early response to drug was important clinically and was significant for enhancing the quality of life of patients. Major adverse reactions were leukopenia and gastrointestinal symptoms such as nausea, vomiting and diarrhea (Grade 2-3). However, these could be well managed by symptomatic treatment and dose modification. The results suggested that CPT-11 was an effective agent against advanced or recurrent breast cancer, and especially useful for patients who had developed a tolerance to previous therapies.

KW - breast cancer

KW - CPT-11

KW - irinotecan

UR - http://www.scopus.com/inward/record.url?scp=0028041276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028041276&partnerID=8YFLogxK

M3 - Article

C2 - 8031169

AN - SCOPUS:0028041276

VL - 21

SP - 1263

EP - 1266

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 8

ER -